© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 3, 167-173,
February 6, 2002
© 2002 Oxford University Press
ARTICLE |
All-Cause Mortality in Randomized Trials of Cancer Screening
Affiliations of authors: W. C. Black, Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, and Department of Community and Family Medicine, Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH; D. A. Haggstrom, Department of Medicine, Dartmouth-Hitchcock Medical Center; H. G. Welch, Department of Medicine, Dartmouth-Hitchcock Medical Center, and Department of Community and Family Medicine, Center for the Evaluative Clinical Sciences, Dartmouth Medical School, and Department of Veterans Affairs Outcomes Group, Department of Veterans Affairs Hospital, White River Junction, VT.
Correspondence to: William C. Black, M.D., Department of Radiology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr., Lebanon, NH 03756 (e-mail: william.black{at}Hitchcock.org).
Background: The most widely accepted end point in randomized cancer screening trials is disease-specific mortality. The validity of this end point, however, rests on the assumption that cause of death can be determined accurately. An alternative end point is all-cause mortality, which depends only on the accurate ascertainment of deaths and when they occur. We compared disease-specific and all-cause mortality in published randomized cancer-screening trials to indirectly assess the validity of the disease-specific mortality end point. Methods: We examined all 12 published randomized trials of cancer screening for which both end points were available (seven of mammography, three of fecal occult blood detection, and two of chest x-ray screening for lung cancer). For each randomized trial, we subtracted disease-specific mortality observed in the screened group from that observed in the control group and all-cause mortality in the screened group from that in the control group. We then compared the differences in these two mortality measures. Results: In five of the 12 trials, differences in the two mortality rates went in opposite directions, suggesting opposite effects of screening. In four of these five trials, disease-specific mortality was lower in the screened group than in the control group, whereas all-cause mortality was the same or higher. In two of the remaining seven trials, the mortality rate differences were in the same direction but their magnitudes were inconsistent; i.e., the difference in all-cause mortality exceeded the disease-specific mortality in the control group. Thus, results of seven of the 12 trials were inconsistent in their direction or magnitude. Conclusion: Major inconsistencies were identified in disease-specific and all-cause mortality end points in randomized cancer screening trials. Because all-cause mortality is not affected by bias in classifying the cause of death, it should be examined when interpreting the results of randomized cancer-screening trials.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. G. Baker Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests J Natl Cancer Inst, August 19, 2009; 101(16): 1116 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shen, J. P. Costantino, and J. Qin Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer J Natl Cancer Inst, October 15, 2008; 100(20): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ravenel, P. Costello, and G. A. Silvestri Screening for Lung Cancer Am. J. Roentgenol., March 1, 2008; 190(3): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Henschke and D. F. Yankelevitz CT Screening for Lung Cancer: Update 2007 Oncologist, January 1, 2008; 13(1): 65 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Obuchowski, P. Schoenhagen, M. T. Modic, M. Meziane, and G. T. Budd Incidence of Advanced Symptomatic Disease as Primary Endpoint in Screening and Prevention Trials Am. J. Roentgenol., July 1, 2007; 189(1): 19 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schoder and M. Gonen Screening for Cancer with PET and PET/CT: Potential and Limitations J. Nucl. Med., January 1, 2007; 48(1_suppl): 4S - 18S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Otto, F. H. Schroder, and H. J. de Koning Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial J. Clin. Oncol., September 1, 2006; 24(25): 4184 - 4189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Pletcher What about other causes of death? Arch Intern Med, July 24, 2006; 166(14): 1528 - 1528. [Full Text] [PDF]
|
|
|
|
|
|
W. C. Black Randomized Clinical Trials for Cancer Screening: Rationale and Design Considerations for Imaging Tests J. Clin. Oncol., July 10, 2006; 24(20): 3252 - 3260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Reich Assessing the Efficacy of Lung Cancer Screening Radiology, February 1, 2006; 238(2): 398 - 401. [Full Text] [PDF]
|
|
|
|
|
|
M. K. Krzyzanowska and I. F. Tannock Should Screen-detected Breast Cancers Be Managed Differently? J Natl Cancer Inst, August 17, 2005; 97(16): 1170 - 1171. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Kroenke, W. Y. Chen, B. Rosner, and M. D. Holmes Weight, Weight Gain, and Survival After Breast Cancer Diagnosis J. Clin. Oncol., March 1, 2005; 23(7): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fleming, E. P. Whitlock, T. L. Beil, and F. A. Lederle Screening for Abdominal Aortic Aneurysm: A Best-Evidence Systematic Review for the U.S. Preventive Services Task Force Ann Intern Med, February 1, 2005; 142(3): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Read, R. M. Tierney, N. C. Page, I. Costas, R. Govindan, E. L.J. Spitznagel, and J. F. Piccirillo Differential Prognostic Impact of Comorbidity J. Clin. Oncol., August 1, 2004; 22(15): 3099 - 3103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Humphrey, S. Teutsch, and M. Johnson Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force Ann Intern Med, May 4, 2004; 140(9): 740 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Mainous III, J. M. Gill, and P. J. Carek Elevated Serum Transferrin Saturation and Mortality Ann. Fam. Med, March 1, 2004; 2(2): 133 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Mainous III, B. Wells, P. J. Carek, J. M. Gill, and M. E. Geesey The Mortality Risk of Elevated Serum Transferrin Saturation and Consumption of Dietary Iron Ann. Fam. Med, March 1, 2004; 2(2): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Baines Mammography Screening: Are Women Really Giving Informed Consent? (Countering the Counterpoint) J Natl Cancer Inst, October 15, 2003; 95(20): 1512 - 1513. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Lederle Ultrasonographic Screening for Abdominal Aortic Aneurysms Ann Intern Med, September 16, 2003; 139(6): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Duffy, L. Tabar, B. Vitak, M. F. Yen, J. Warwick, R. A. Smith, and H. H. Chen The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation Ann. Onc., August 1, 2003; 14(8): 1196 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Anorbe, P. Aisa, and V. P. Jackson Screening Mammography [letter] * Dr Jackson responds: Radiology, June 1, 2003; 227(3): 903 - 904. [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Wilt Radical prostatectomy reduced death from prostate cancer but not all cause mortality Evid. Based Med., March 1, 2003; 8(2): 41 - 41. [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, M. J. Kelley, R. C. Tate, and D. C. McCrory Screening for Lung Cancer: A Review of the Current Literature Chest, January 1, 2003; 123 (2009): 72S - 82S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Black and M. N. Brant-Zawadzki Invited Commentary * Author's Response RadioGraphics, November 1, 2002; 22(6): 1536 - 1539. [Full Text] [PDF]
|
|
|
|
|
|
L. L. Humphrey, M. Helfand, B. K.S. Chan, and S. H. Woolf Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, September 3, 2002; 137(5_Part_1): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Goodman The Mammography Dilemma: A Crisis for Evidence-Based Medicine? Ann Intern Med, September 3, 2002; 137(5_Part_1): 363 - 365. [Full Text] [PDF]
|
|
|
|
|
|
E. Anorbe, P. Aisa, E. F. Patz, W. C. Black, and P. C. Goodman Mortality Rate and Screening * Dr Patz and colleagues respond: Radiology, September 1, 2002; 224(3): 929 - 930. [Full Text] [PDF]
|
|
|
|
|
|
H. G. Welch and W. C. Black Are Deaths Within 1 Month of Cancer-Directed Surgery Attributed to Cancer? J Natl Cancer Inst, July 17, 2002; 94(14): 1066 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Church, F. Ederer, and J. S. Mandel Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 861 - 860. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail and H. A. Katki Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 862 - 862. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Kopans and E. Halpern Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 863 - 863. [Full Text] [PDF]
|
|
|
|
|
|
N. S. Weiss and T. D. Koepsell Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 864 - 865. [Full Text] [PDF]
|
|
|
|
|
|
C. B. Begg and P. B. Bach Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 863 - 864. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey Eur J Heart Fail, June 1, 2002; 4(3): 243 - 247. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Moynihan, I. Heath, D. Henry, and P. C Gotzsche Selling sickness: the pharmaceutical industry and disease mongering * Commentary: Medicalisation of risk factors BMJ, April 13, 2002; 324(7342): 886 - 891. [Full Text] [PDF]
|
|
|
|
|
|
H. G. Juffs and I. F. Tannock Screening Trials Are Even More Difficult Than We Thought They Were J Natl Cancer Inst, February 6, 2002; 94(3): 156 - 157. [Full Text] [PDF]
|
|